Cantil

Quick links to important sections

Cantil

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cantil

What is Cantil? Mepenzolate Bromide Overview

Property Description
Active Ingredient Mepenzolate bromide
Form Oral tablet
Pharmacological Class Anticholinergic (Antimuscarinic) Agent
General Purpose Reduction of gastrointestinal spasm and secretion
Origin Synthetic organic compound

Defining Cantil: Identity and Pharmacological Class

Cantil is a prescription medicine containing mepenzolate bromide, a synthetic organic compound that serves as its active ingredient. The compound is officially classified as an anticholinergic agent, specifically belonging to the subgroup of antimuscarinic agents. Chemically, mepenzolate bromide is identified as a quaternary ammonium compound—a structure clinically recognized to focus its effects primarily on the peripheral nervous system rather than the brain. This design limits its systemic distribution, prioritizing therapeutic action on the smooth muscles and secretory glands of the digestive tract.


Composition, Form, and General Purpose

The medication is a single-entity product primarily administered via the oral route in the form of a tablet. Although certain dosage forms of the original brand have been subject to regulatory status changes, the generic compound mepenzolate bromide remains referenced for its established mechanism. Its general therapeutic purpose is to provide symptomatic relief by addressing hypermotility (excessive movement) and hypersecretion (excessive fluid release). It functions as a postganglionic parasympathetic inhibitor to relax the bowel's smooth muscles, achieving an antispasmodic effect, and concurrently reduces the output of digestive fluids like gastric acid and pepsin. This dual-action mechanism means the medicine is intended as an adjunctive therapy—a supportive addition to treatment—aimed at soothing an irritated or overactive digestive system, such as in cases where severe cramping discomfort is present.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Cantil?

Official Regulatory Safety Profile

This section summarizes the adverse reactions and safety information for Cantil (mepenzolate bromide) as documented in authoritative governmental regulatory sources.

Adverse Reactions Scope

Cantil is an anticholinergic medicine, and its adverse effects are primarily related to this class of action. The most common or expected effects involve several System-Organ Classes (SOCs):

  • Eye Disorders: Blurred vision and cycloplegia.
  • Gastrointestinal Disorders: Dry mouth and constipation.
  • Renal and Urinary Disorders: Urinary hesitancy or urinary retention.
  • Cardiac Disorders: Tachycardia (rapid heartbeat) and palpitations.
  • Nervous System and Psychiatric Disorders: Headache, dizziness, drowsiness, nervousness, excitement, and mental confusion.

Serious and Clinically Significant Safety Information

Regulatory documents highlight several serious concerns and warnings, including:

  • Heat Prostration: A significant risk due to the drug’s ability to reduce sweating (anhidrosis), particularly when used in a hot environment.
  • Toxic Psychosis: Potentially characterized by excitement, agitation, drowsiness, visual hallucinations, and confusion, especially in susceptible individuals like the elderly.
  • Risk of Obstruction: Diarrhea may be a symptom of a partially obstructed intestine, and the use of this drug in such a scenario can be dangerous. It may also precipitate acute glaucoma or cause toxic megacolon in severe ulcerative colitis.

Safety-Related Restrictions and Contraindications

Cantil is strictly restricted and contraindicated (should not be used) in patients with specific health conditions due to high risk:

  • Glaucoma (especially angle-closure glaucoma).
  • Obstructive diseases of the urinary tract (e.g., prostatic hypertrophy).
  • Obstructive diseases of the gastrointestinal tract (e.g., paralytic ileus, pyloroduodenal stenosis, intestinal atony).
  • Severe ulcerative colitis or toxic megacolon.
  • Myasthenia gravis.
  • Known hypersensitivity to the drug.

Population-Specific Considerations

Geriatric Patients show increased sensitivity to the central nervous system anticholinergic effects, such as mental confusion. Pregnancy risk is rated Category C (risk not ruled out), and Pediatric Use safety has not been established.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cantil (mepenzolate bromide) is officially documented by the presentation of pronounced anticholinergic manifestations. The recognized clinical signs include CNS stimulation, blurred vision, dilated pupils, hot, dry skin, dryness of the mouth, and difficulty in swallowing, along with headache, dizziness, nausea, and vomiting.


Severe and Life-Threatening Outcomes

The official prescribing information warns of the potential for severe escalation, characterized by a curare-like action resulting in neuromuscular blockade, muscular weakness, and possible paralysis. Overdose has been associated with fatal outcomes; specifically, a dose of 500 to 750 mg was recorded as resulting in death in a 30-year-old adult. Regulatory notes also include a dose of 375 to 500 mg recorded as not resulting in adverse effects in a 4-year-old child.


Emergency Medical Actions Required

Immediate medical attention is necessary if an overdose is suspected, due to the critical nature of the documented severe effects. Treatment described in official regulatory text includes procedures such as gastric lavage, administration of activated charcoal, and the potential use of a parenteral cholinergic agent as an antidote. Sedatives like short-acting barbiturates or benzodiazepines may also be required for the management of overt excitement.

Therapeutic Uses of Cantil

Cantil's Role in Digestive System Management

Cantil is a prescribed agent used as an adjunct in the therapeutic management of peptic ulcers. Its mechanism of action involves diminishing the secretion of gastric acid and pepsin, which helps in the overall management of the condition. By exerting this effect, the compound assists in controlling the physiological factors associated with ulcer symptoms.

Cantil is utilized in a supportive role, meaning it is administered along with other required treatments for ulcer disease.


Quick Facts

  • Targeted Condition: Peptic ulcers.
  • Therapeutic Purpose: Adjunctive management of ulcer disease.
  • Mechanism Benefit: Decreases gastric acid and pepsin secretion.

Eligibility and Restrictions for Use

Cantil (Mepenzolate Bromide) is governed by strict population eligibility rules outlined in official regulatory documents.


Who Must Not Use Cantil (Contraindications)

The medicine is contraindicated and must not be used by patients diagnosed with specific health conditions that involve physical obstruction or neuromuscular compromise. These absolute exclusions include glaucoma, obstructive disease of the gastrointestinal tract (including conditions like pyloroduodenal stenosis), obstructive uropathy (such as bladder neck obstruction), and conditions like paralytic ileus or intestinal atony. Cantil is also prohibited for patients with myasthenia gravis, toxic megacolon, or unstable cardiovascular status in acute gastrointestinal hemorrhage.


Restricted and Conditional Use

Eligibility is restricted and requires caution in populations presenting with compromised function. This includes patients with hepatic disease, renal disease, and various underlying cardiovascular conditions (including cardiac arrhythmias and congestive heart failure). Use in the elderly is restricted due to specific risks. Regulatory information notes that use is not established in the pediatric population. For nursing mothers, the label indicates a potential for suppression of lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Statements

Co-administration with solid oral dosage forms of Potassium Chloride or Potassium Citrate is contraindicated. This restriction is mandatory due to the officially documented risk of an enhanced ulcerogenic effect in the gastrointestinal tract.

The drug’s anticholinergic properties result in an additive pharmacodynamic effect when combined with other agents that possess similar activity, such as MAO Inhibitors or Narcotic Analgesics. This reinforcement increases the regulatory-noted potential for enhanced adverse effects.

Cantil may antagonize the therapeutic action of certain medicines, including antigalucoma agents and drugs intended to increase gastrointestinal motility (prokinetics). Furthermore, the delay in gastric emptying can affect absorption, potentially leading to increased serum concentrations of slowly dissolving Digoxin formulations.

Timing-Based Rules and Substance Restrictions

Simultaneous use with antacids must be avoided, as official documents note that antacids may interfere with the drug’s absorption. Caution is also noted regarding alcohol, which may enhance central nervous system effects like drowsiness.

Regulatory prescribing information notes that anticholinergic effects may be more pronounced in the elderly. It also advises caution when co-administering with corticosteroids in the presence of increased intraocular pressure.


The official interaction profile is structured around mandatory restrictions for certain potassium salts and cautions for pharmacodynamic and pharmacokinetic interactions as defined in the government labeling. The constraints primarily address additive effects and altered absorption due to the drug’s effects on gastrointestinal function.

Mechanism of Action

How Cantil Works

Cantil exerts its pharmacodynamic action by operating as a selective antagonist at specific muscarinic acetylcholine receptors ( M1 and M3) located within the gastrointestinal tract. By occupying the binding sites of these receptors, the drug directly blocks the natural neurotransmitter acetylcholine from initiating cellular activity. This interaction effectively interrupts the excitatory signals transmitted via the parasympathetic nervous system pathways that regulate involuntary digestive functions.

This specific molecular event initiates a cholinergic cascade inhibition, modifying the early cellular steps required for smooth muscle contraction and glandular secretion. The resulting effect is a modulation of the two key physiological processes in the gut: motility and secretion. This targeted pathway interference influences the frequency and force of muscular activity, leading to a predictable physiological adjustment in the activity level within the smooth muscle and glandular tissues.

Dosage and Administration Information

How Cantil is Used: Administration Guidelines

Cantil, which contains mepenzolate bromide, is a prescription medicine administered via the oral route in the form of a 25 mg tablet. The dosing pattern involves taking the medicine 4 times a day (quad daily), and the schedule is specifically tied to meal times and the sleep period, with doses taken with meals and at bedtime.


Dosing and Frequency

The standard adult dose ranges from 25 mg to 50 mg per administration. Standard guidelines advise starting at the lower dosage of 25 mg and adjusting based on the patient's individual clinical response. This ensures the medication is used at the lowest necessary dose. If a dose is missed, it is generally suggested to skip the missed dose and not take extra medication to catch up, instead resuming the regular schedule at the next scheduled time.


Population-Specific Considerations

Specific guidance exists for certain patient populations. For older adults (geriatric patients), caution is necessary, and dose selection should begin at the low end of the dosing range. Furthermore, mepenzolate bromide should be used with caution in individuals with existing hepatic or renal disease. The safety and effectiveness of mepenzolate bromide have not been established for use in pediatric patients (children).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cantil

This section provides an overview of the research and studies that have examined Cantil (mepenzolate bromide). The information is structured to describe what was studied and what was reported, while transparently identifying the remaining uncertainties in the evidence.


Evidence for Use in Peptic Ulcer Disease (Adjunct Therapy)

The research that established the study of Cantil as an auxiliary or supportive treatment for conditions involving peptic ulcer symptoms and hypersecretion primarily comes from early Clinical Trials and Comparative Studies. These studies explored outcomes related to physical discomfort and systemic imbalance. In this research, studies explored whether the compound's use alongside other treatments was associated with changes in specific measured outcomes. Research examined physiological changes, specifically monitoring levels of gastric acid secretion and pepsin. Research monitored levels of these secretions, and findings described patterns of measured change during the study periods.

Furthermore, research examined outcomes related to the rate of ulcer healing observed in some studies, but the reported outcomes were not uniform across the evidence base. It is important to note that the primary evidence base for this application is Historical, meaning it was gathered before the widespread use of modern and potent acid-suppressing therapies. As a result, the evidence contributes to the broader understanding of older treatment patterns, but limited information for long-term outcomes is available, and data for its use alongside current therapies remain insufficient.


Research on Gastrointestinal Spasm and Motility

Research dedicated to Cantil's study as an antispasmodic agent involves Pharmacodynamic Studies and clinical trials. This research explores short-term symptom changes in conditions involving periods of heightened symptoms, such as abdominal cramping, with studies that examined outcomes related to GI hypermotility, muscle contractions, and patient-reported discomfort. Pharmacodynamic research examined physiological changes, and findings described patterns related to spontaneous contractions within the digestive tract. In clinical trials, studies reported how symptoms evolved in the observed populations, and findings described patterns where patient-reported outcomes related to abdominal pain and cramping evolved during the study period.

However, the specific research available for mepenzolate bromide for functional motility disorders is limited compared to the general body of evidence for the broader class of antispasmodic agents. Furthermore, the evidence derived from settings with varying symptom burdens typically covers only short-term or intermediate periods, providing limited information about long-lasting changes.


Research Gaps and Areas of Uncertainty

The evidence landscape for Cantil highlights several areas where knowledge is incomplete or uncertain. Due to the historical nature of the primary evidence base, comparative evidence is lacking regarding its study against treatments used in the current era. Follow-up durations were limited, resulting in insufficient data for long-term outcomes. Additionally, research examined the compound’s relationship to secretion and spasm. The data show patterns related to group results, but research does not determine whether an individual will respond similarly. Studies help show what has been observed so far, but certainty remains low regarding the full spectrum of its study in the current era.

Key Studies & References Mepenzolate Bromide - NIH LiverTox Clinical and Research Information on Drug-Induced Liver Injury

Frequently Asked Questions (FAQ)

Common questions about Cantil (FAQ)


Q: Is Cantil the same as other medicines for similar conditions?

Cantil belongs to the pharmacological class of anticholinergic (antimuscarinic) agents. This classification indicates it is one of several medicines that act on this specific receptor type in the body. Its defined therapeutic purpose is to achieve an antispasmodic effect by reducing excessive movement and secretion in the digestive system.


Q: Is there a generic version of Cantil available?

Official records indicate that the Cantil brand name tablet formulation is a discontinued product. Consequently, a generic version of mepenzolate bromide is not widely listed as currently marketed or available.


Q: Is Cantil available in a liquid form or only tablets?

The currently referenced form for the drug is an oral tablet. Official records indicate that a solution form was previously approved but has since been discontinued.


Q: Do I need to take Cantil at a specific time of day?

Official dosing directions state the medicine is administered four times a day. The schedule is specifically tied to meal times and the sleep period, with doses preferably taken with meals and at bedtime.


Q: What should I do if I miss a dose of Cantil?

Official regulatory guidance generally describes skipping the missed dose and not taking extra medication to catch up. The guidance suggests resuming the regular schedule at the next scheduled time.


Q: Does Cantil change how my body absorbs other medicines?

The drug works by slowing movement in the digestive system. This effect can delay gastric emptying, a process which may potentially affect the absorption of other medicines. This caution is specifically noted for certain slowly dissolving oral dosage forms like Digoxin.


Q: Can Cantil be taken with over-the-counter pain relievers?

The official interaction profile specifically mentions additive effects when combined with narcotic analgesics. However, the general regulatory labeling does not uniformly address all common over-the-counter pain relievers.


Q: Does Cantil interact with commonly prescribed blood pressure medications?

The official interaction profile notes that the drug may antagonize the therapeutic action of certain antiglaucoma agents. Specific interactions with all common blood pressure medicines are not uniformly detailed in the general regulatory labeling.


Q: How quickly can I expect to notice any effects from Cantil?

Official documents indicate the drug is a quaternary ammonium compound, and its absorption following oral administration is described as low. A specific timeframe for when symptom relief can be expected is not provided in the general labeling.


Q: How long does Cantil typically stay in the body?

A specific elimination half-life is not readily available in general regulatory summaries. Excretion data shows that the majority of the absorbed dose that is ultimately excreted is eliminated within the first day.


Q: Does Cantil cause sleepiness or drowsiness?

Drowsiness is listed in the official safety profile as a potential adverse reaction. This is a type of Central Nervous System symptom related to the drug's anticholinergic class.


Q: Is it normal to have a dry mouth while taking Cantil?

Dry mouth is listed in the official safety profile as a reported anticholinergic adverse reaction. This reported effect is related to the drug’s anticholinergic mechanism, which is known to influence secretions in the body.


Q: Why do some people say Cantil makes them dizzy?

Dizziness is a reported adverse effect that is listed as a Central Nervous System symptom. This reported symptom is generally understood to be related to the drug's anticholinergic class effects on the Central Nervous System.


Q: What are the most frequent patient complaints about Cantil?

Reported effects cited in official documents include anticholinergic symptoms such as dry mouth and constipation. However, official labeling notes that precise frequency data from controlled clinical studies are not widely available.


Q: Can Cantil cause changes in mood or behavior?

Regulatory warnings note the risk of toxic psychosis. This condition can be characterized by changes in behavior and mood, including excitement, agitation, drowsiness, confusion, and visual hallucinations.


Q: Can Cantil affect my ability to drive or operate machinery?

Official labeling describes the potential for blurred vision or drowsiness. A caution is issued regarding activities requiring mental alertness, such as operating a motor vehicle or machinery.


Q: Do different strengths of Cantil have different side effect profiles?

The official dosing information advises beginning at the lower dosage and adjusting based on the patient's individual clinical response. This guidance implicitly acknowledges that the dose strength is related to the potential for clinical effects and adverse reactions.


Q: What are the reasons someone might need to switch from Cantil to another medicine?

Reasons for discontinuation or switching often relate to the experience of intolerable adverse effects or a lack of therapeutic response. Another reason could be the development of a health condition that is now listed as a contraindication.


Q: What is the purpose of the 'inactive' ingredients in Cantil tablets?

Inactive ingredients, known as excipients, serve necessary roles in the tablet formulation. They are used to help hold the tablet together, give it bulk, and help the body absorb the active medicine, as described in general drug composition guidelines.


Q: Is Cantil safe to take while breastfeeding?

Regulatory-related information notes a potential for suppression of lactation (milk production). While direct data on use during breastfeeding is limited, its drug class is known to influence milk production.

How should Cantil be stored and disposed of?

Official Storage and Disposal Instructions for Cantil (Mepenzolate Bromide)

According to regulatory labeling, Cantil must be stored at controlled room temperature, specifically below 86 F (30 C). It is essential to protect the medication from excessive heat to maintain product integrity.

Handling and Packaging Requirements

  • Container Protection: The product must be kept in a tight container and this container must be kept tightly closed when not in use.
  • Child Safety: When dispensed, the product is required to have a child-resistant closure to prevent accidental ingestion.

Disposal

The official drug label does not provide specific instructions for the disposal of unused or expired Cantil. Patients should consult their pharmacist or local waste management facility for proper disposal guidelines in accordance with applicable regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cantil found in:

A-Z Index: